Immune monitoring and biomarkers to predict chronic allograft dysfunction

Kidney International

Volumn 78, Issue SUPPL. 119, 2010, Pages

  Mannon, Roslyn B ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; biopsy; ELISpot; monitoring; proteomics; transplantation

Indexed keywords

BIOLOGICAL MARKER; CREATININE; MESSENGER RNA; PLASMA PROTEIN;

ANTIBODY BLOOD LEVEL; BIOPSY TECHNIQUE; CHRONIC ALLOGRAFT DYSFUNCTION; CHRONIC GRAFT REJECTION; CONFERENCE PAPER; CREATININE BLOOD LEVEL; GENOMICS; GRAFT FAILURE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT; METABOLOMICS; MICROENVIRONMENT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; SENSITIVITY ANALYSIS; URINALYSIS;

EID: 78649640919     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.425     Document Type: Conference Paper

References (73)

1. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
2. Azuma H, Tilney NL. Immune and nonimmune mechanisms of chronic rejection of kidney allografts. J Heart Lung Transplant 1995; 14: S136-S142.
3. Halloran PF. Call for revolution: a new approach to describing allograft deterioration. Am J Transplant 2002; 2: 195-200.
4. Racusen LC, Solez K, Colvin R. Fibrosis and atrophy in the renal allograft: interim report and new directions. Am J Transplant 2002; 2: 203-206.
5. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria -an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
6. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
7. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
8. Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF Study. Am J Transplant 2009; 9: 315-323.
9. Sis B, Einecke G, Chang J et al. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant 2010; 10: 421-430.
10. Halloran PF, Schlaut J, Solez K et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
11. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
12. Akalin E, Dinavahi R, Dikman S et al. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007; 2: 1261-1267.
13. Sis B, Jhangri GS, Bunnag S et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
14. Cosio FG, Grande JP, Wadei H et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
15. Moreso F, Ibernon M, Goma M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
16. Mengel M, Reeve J, Bunnag S et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9: 1859-1867.
17. Cravedi P, Mannon RB. Non-invasive methods to assess the risk of kidney transplant rejection. Expert Rev Clin Immunol 2009; 5: 535-546.
18. Mannon RB, Kirk AD. Beyond histology: novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol 2006; 1: 358-366.
19. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008; 86: 192-199.
20. Mannon RB. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 2006; 6: 867-875.
21. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
22. Gerbase-DeLima M, Campos EF, Tedesco-Silva H et al. Anti-HLA class II antibodies and chronic allograft nephropathy. Clin Transpl 2006: 201-205.
23. Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192-1194.
24. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
25. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438-443.
26. Worthington JE, Martin S, Al Husseini DM et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034-1040.
27. Susal C, Dohler B, Sadeghi M et al. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation 2009; 87: 1367-1371.
28. Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
29. Joosten SA, van Dixhoorn MG, Borrias MC et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301-1310.
30. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
31. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
32. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
33. Campistol JM, Inigo P, Larios S et al. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 2001; 16(Suppl 1): 114-116.
34. Sharma VK, Bologa RM, Xu GP et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297-1303.
35. Mas V, Maluf D, Archer K et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007; 83: 448-457.
36. Cheng O, Thuillier R, Sampson E et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6: 2292-2306.
37. Raj DS, Lim G, Levi M et al. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy. Am J Kidney Dis 2004; 43: 154-160.
38. Sezer S, Akcay A, Ozdemir FN et al. Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant 2004; 18: 722-725.
39. Weimer R, Susal C, Yildiz S et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006; 6: 1865-1874.
40. Rodder S, Scherer A, Raulf F et al. Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. Am J Transplant 2009; 9: 517-526.
41. Ashton-Chess J, Giral M, Mengel M et al. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol 2008; 19: 1116-1127.
42. Dinavahi R, Heeger PS. T-cell immune monitoring in organ transplantation. Transplantation 2009; 88: 1157-1158.
43. Heeger PS, Greenspan NS, Kuhlenschmidt S et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275.
44. Augustine JJ, Siu DS, Clemente MJ et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971-1975.
45. Hricik DE, Rodriguez V, Riley J et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3: 878-884.
46. Kurian SM, Heilman R, Mondala TS et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009; 4: e6212.
47. Clarke W, Silverman BC, Zhang Z et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003; 237: 660-664.
48. O'riordan E, Orlova TN, Mei JJ et al Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004 15 3240-3248.
49. Wittke S, Haubitz M, Walden M et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005; 5: 2479-2488.
50. Quintana LF, Sole-Gonzalez A, Kalko SG et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20: 428-435.
51. Quintana LF, Campistol JM, Alcolea MP et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics 2009; 8: 1658-1673.
52. Banon-Maneus E, Diekmann F, Carrascal M et al. Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation 2010; 89: 548-558.
53. Rush D, Somorjai R et al. Urine magnetic resonance spectroscopy (UMRS): results from the DeKAF study. (abstract) Am J Transplant 2009; 9 (Suppl 2): 350.
54. Puigmule M, Lopez-Hellin J, Sune G et al. Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells. Nephrol Dial Transplant 2009; 24: 2672-2686.
55. Bone JM, Amara AB, Shenkin A et al. Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy. Transplantation 2005; 79: 119-122.
56. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
57. Mas VR, Mas LA, Archer KJ et al. Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function. Mol Med 2007; 13: 315-324.
58. Tatapudi RR, Muthukumar T, Dadhania D et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390-2397.
59. Einecke G, Broderick G, Sis B et al. Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7: 1121-1130.
60. Einecke G, Melk A, Ramassar V et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005; 5: 1827-1836.
61. Famulski KS, Einecke G, Reeve J et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342-1354.
62. Famulski KS, Kayser D, Einecke G et al. Alternative macrophage activation-associated transcripts in T-Cell-mediated rejection of mouse kidney allografts. Am J Transplant 2010; 10: 490-497.
63. Mueller TF, Einecke G, Reeve J et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712-2722.
64. Avihingsanon Y, Ma N, Pavlakis M et al. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol 2005; 16: 1542-1548.
65. Hoffmann SC, Kampen RL, Amur S et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 2002; 74: 916-923.
66. Hoffmann SC, Hale DA, Kleiner DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573-581.
67. Mannon RB, Hoffmann SC, Kampen RL et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005; 5: 2883-2893.
68. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006-2012.
69. Choi BS, Shin MJ, Shin SJ et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5: 1354-1360.
70. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. Transplantation 1995; 59: 511-514.
71. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046-1052.
72. Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129-2134.
73. Rush D, Arlen D, Boucher A et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7: 2538-2545.